SoFi CEO enters prepaid forward contract on 1.5 million shares
Danaher Corporation (NYSE:DHR) stock has experienced a notable downturn, reaching a 52-week low of $225.36. With a market capitalization of $163 billion, InvestingPro analysis indicates the stock is currently trading above its Fair Value. This recent price level reflects a challenging period for the science and technology innovator, as investors recalibrate their portfolios in response to broader market trends. Trading at a P/E ratio of 42.8, the stock has attracted attention from Wall Street analysts, with consensus targets ranging from $250 to $315. Despite the company’s diverse portfolio and strong presence in the diagnostics and research sectors, maintaining an overall "GOOD" Financial Health Score, the stock has not been immune to the pressures affecting the global markets, leading to this new one-year low. Discover more comprehensive insights and 12 additional ProTips for DHR through InvestingPro’s detailed research reports.
In other recent news, Danaher Corporation experienced a series of significant developments. The company’s shares climbed following robust financial results from German life sciences company Sartorius AG (ETR:SATG), which led to positive market responses for Sartorius’s US-listed peers, including Danaher. Analysts from Barclays (LON:BARC) and JPMorgan attributed Sartorius’s strong performance to high demand for consumables, particularly for advanced therapies.
Furthermore, new export controls on biotechnology equipment announced by the U.S. Commerce Department impacted shares of various companies in the sector, including Danaher. These regulations aim to prevent the use of U.S. technology by China in military applications, potentially disrupting the sales and supply chains of affected companies.
RBC analyst Conor McNamara expressed optimism about Danaher’s future, highlighting improving visibility in the company’s end-markets and anticipating a return to historical growth levels by the second half of 2025. On another note, Guggenheim initiated coverage on Danaher shares with a Buy rating and set a price target of $275.00, underscoring Danaher’s standing as a leader in the bioprocessing industry.
Finally, Danaher Corporation projected a low-single digit percentage increase in its revenues for the fourth quarter of 2024 compared to the same period the previous year, indicating a performance that exceeds the company’s earlier expectations of a decline. These are the recent developments for Danaher Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.